NfL (Neurofilament Light Chain) Levels as a Predictive Marker for Long-Term Outcome After Ischemic Stroke
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Background and Purpose—: Ischemic stroke causes major disability as a consequence of neuronal loss and recurrent ischemic events. Biomarkers predicting tissue damage or stroke recurrence might be useful to guide an individualized stroke therapy. NfL (neurofilament light chain) is a promising biomarker that might be used for this purpose. Methods—: We used individual data of patients with an acute ischemic stroke and clinical long term follow-up. Serum NfL (sNfL) was quantified within 24 hours after admission and after 1 year and compared with other biomarkers (GDF15 [growth differentiation factor 15], S100, NT-proBNP [N-terminal pro-B-type natriuretic peptide], ANP [atrial natriuretic peptide], and FABP [fatty acid–binding protein]). The primary end point was functional outcome after 90 days and cerebrovascular events and death (combined cardiovascular end point) within 36 months of follow-up. Results—: Two hundred eleven patients (mean age, 68.7 years; SD, ±12.6; 41.2% women) with median clinical severity on the National Institutes of Health Stroke Scale (NIHSS) score of 3 (interquartile range, 1–5) and long-term follow-up with a median of 41.8 months (interquartile range, 40.0–44.5) were prospectively included. We observed a significant correlation between sNfL and NIHSS at hospital admission (r=0.234; P <0.001). sNfL levels increased with the grade of age-related white matter changes ( P <0.001) and were able to predict unfavorable clinical outcome (modified Rankin Scale score, ≥2) 90 days after stroke (odds ratio [OR], 1.562; 95% CI, 1.003–2.433; P =0.048) together with NIHSS (OR, 1.303; 95% CI, 1.164–1.458; P <0.001) and age-related white matter change rating (severe; OR, 3.326; 95% CI, 1.186–9.326; P =0.022). Similarly, sNfL was valuable for the prediction of the combined cardiovascular end point (OR, 2.002; 95% CI, 1.213–3.302; P =0.007), besides NIHSS (OR, 1.110; 95% CI, 1.000–1.232; P =0.049), diabetes mellitus (OR, 2.942; 95% CI, 1.306–6.630; P =0.005), and age-related white matter change rating (severe; OR, 4.816; 95% CI, 1.206–19.229; P =0.026) after multivariate regression analysis. Kaplan-Meier analysis revealed significantly more combined cardiovascular end points (18 [14.1%] versus 38 [45.8%], log-rank test P <0.001) during long-term follow-up in patients with elevated sNfL levels. Conclusions—: sNFL is a valuable biomarker for functional independence 90 days after ischemic stroke and predicts cardiovascular long-term outcome. Clinical Trial Registration—: URL: http://www.isrctn.com . Unique identifier: ISRCTN 46104198.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The metabolic syndrome—a new worldwide definition
Alberti, K. G. M., Zimmet, P., & Shaw, J. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67402-8 · Cited by 9,352
Debette, S., & Markus, H. S. (2010) · BMJ · doi:10.1136/bmj.c3666 · Cited by 2,328 · cited 1×
“ongoing chronic axonal damage and progression of chronic small vessel disease,(29) both linked to recurrent cerebral ischemia(12,13,30,31) and death.(13)”
BackgroundNeurofilaments as biomarkers in neurological disorders
Khalil, M., Teunissen, C. E., Otto, M., Piehl, F., Sormani, M. P., Gattringer, T., Barro, C., Kappos, L., Comabella, M., Fazekas, F., et al. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0058-z · Cited by 1,988 · cited 2×
“Ultrasensitive assays with the single molecule array method enable highly sensitive quantification of NfL in the blood.(4) As a consequence of this easy and broad applicability, the research on NfL in various diseases such as multiple sclerosis(5,6) and different neurodegenerative diseases(7,8) is emerging.”
BackgroundMethodAssociation of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease
Mattsson, N., Andreasson, U., Zetterberg, H., Blennow, K., & Initiative, F. T. A. D. N. (2017) · JAMA Neurology · doi:10.1001/jamaneurol.2016.6117 · Cited by 1,070
Barro, C., Benkert, P., Disanto, G., Tsagkas, C., Amann, M., Naegelin, Y., Leppert, D., Gobbi, C., Granziera, C., Yaldizli, Ö., et al. (2018) · Brain · doi:10.1093/brain/awy154 · Cited by 517
Serum neurofilament light chain levels are related to small vessel disease burden
Duering, M., Konieczny, M. J., Tiedt, S., Baykara, E., Tuladhar, A. M., Leijsen, E. V., Lyrer, P., Engelter, S. T., Gesierich, B., Achmüller, M., et al. (2018) · Journal of Stroke · doi:10.5853/jos.2017.02565 · Cited by 132
Cited by
Post-Stroke Cognitive Impairment and Dementia
Rost, N. S., Brodtmann, A., Pase, M. P., van Veluw, S. J., Biffi, A., Duering, M., Hinman, J. D., & Dichgans, M. (2022) · Circulation Research · doi:10.1161/circresaha.122.319951 · Cited by 790
Neurofilaments as biomarkers in neurological disorders — towards clinical application
Khalil, M., Teunissen, C. E., Lehmann, S., Otto, M., Piehl, F., Ziemssen, T., Bittner, S., Sormani, M. P., Gattringer, T., Abu-Rumeileh, S., et al. (2024) · Nature Reviews Neurology · doi:10.1038/s41582-024-00955-x · Cited by 446
Self-citationBlood neurofilament light: a critical review of its application to neurologic disease
Barro, C., Chitnis, T., & Weiner, H. L. (2020) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51234 · Cited by 296
Plasma neurofilament light predicts mortality in patients with stroke
Gendron, T. F., Badi, M. K., Heckman, M. G., Jansen-West, K. R., Vilanilam, G. K., Johnson, P. W., Burch, A. R., Walton, R. L., Ross, O. A., Brott, T. G., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aay1913 · Cited by 92
van den Bosch, A., Fransen, N., Mason, M., Rozemuller, A. J., Teunissen, C., Smolders, J., & Huitinga, I. (2022) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000001154 · Cited by 58
“33 Brain atrophy in MS can also be a source of increases in NfL, 23 but in our study it did not have an effect on CSF NfL levels.”
Vollmuth, C., Fiessler, C., Montellano, F. A., Kollikowski, A. M., Essig, F., Oeckl, P., Barba, L., Steinacker, P., Schulz, C., Ungethüm, K., et al. (2024) · European Stroke Journal · doi:10.1177/23969873241234436 · Cited by 38
“7,26,27 24 Although these studies showed significant associations of serum NfL and GFAP with outcome, the incremental prognostic value of these two biomarkers has not been determined yet.”
Background
Metadata
- Authors
- Uphaus, T., Bittner, S., Gröschel, S., Steffen, F., Muthuraman, M., Wasser, K., Weber-Krüger, M., Zipp, F., Wachter, R., & Gröschel, K.
- Venue
- Stroke
- Published
- 2019-11
- Volume
- 50
- Issue
- 11
- Pages
- 3077-3084
- ISSN
- 0039-2499 (ISSN-L)
- 1524-4628
- OpenAlex
- W2974879600
- Cited by
- 154
- References
- 6
- FWCI
- 12.09
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.